Home › Funds › Mount Capital Ltd › MRNA
Mount Capital Ltd position in MRNA
MODERNA INC · Health Care
Mount Capital Ltd reported holding 230,416 shares of MRNA (MODERNA INC) in its Q3 2026 13F filing — a position valued at US$44.4M, representing 13.94% of its reported portfolio and ranking #2 among its reported holdings. Mount Capital Ltd has disclosed MRNA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How Mount Capital Ltd's MRNA position evolved
Mount Capital Ltd first disclosed a stake in MRNA in Q1 2026 at 395,200 shares (US$20.1M). The position peaked in Q3 2026 at 230,416 shares, worth US$44.4M. Across 3 filings, Mount Capital Ltd increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 230,416 shares valued at US$44.4M — a reduction of -227,484 shares quarter over quarter.. Notable position changes include a 50% trim in Q3 2026 (shares rose 16% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 395.20K | $20.08M | New |
| Q2 2026 | 457.90K | $32.07M | Add |
| Q3 2026 | 230.42K | $44.37M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About MRNA and 13F data
MRNA (MODERNA INC) is a Health Care company. 42 other funds we track also report a position in MRNA — the largest reported positions include Fidelity Management & Research (FMR) (US$11.35B), Capital World Investors (US$4.36B), Baillie Gifford & Co (US$2.20B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding MRNA
- Fidelity Management & Research (FMR) 58.96M sh · $11.35B · Q3 2026
- Capital World Investors 22.64M sh · $4.36B · Q3 2026
- Baillie Gifford & Co 11.44M sh · $2.20B · Q3 2026
- IMC-Chicago, LLC 3.07M sh · $590.92M · Q3 2026
- Theleme Partners LLP 8.06M sh · $564.27M · Q2 2026
- BANQUE PICTET & CIE SA 2.15M sh · $414.27M · Q3 2026
- Flagship Pioneering, LLC 4.63M sh · $324.39M · Q2 2026
- a16z Perennial Management, L.P. 1.52M sh · $292.57M · Q3 2026
- Douglas Lane & Associates, LLC 1.16M sh · $223.56M · Q3 2026
- Beau Ventures, LLc 1.00M sh · $192.58M · Q3 2026
- Merck & Co., Inc. 2.31M sh · $161.64M · Q2 2026
- Lingotto Investment Management LLP 749.21K sh · $144.27M · Q3 2026
More on Mount Capital Ltd
FAQ
How long has Mount Capital Ltd held MRNA?
Mount Capital Ltd has disclosed MRNA holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Mount Capital Ltd's current position in MRNA?
As of Q3 2026, Mount Capital Ltd holds 230.42K shares of MRNA (MODERNA INC), valued at $44.37M, representing 13.94% of its reported portfolio and ranking #2.
Has Mount Capital Ltd been buying or selling MRNA?
In the latest 13F filing (Q3 2026), Mount Capital Ltd reduced its position in MRNA. The position peaked in Q3 2026 at 230.42K shares.
Which other funds hold MRNA?
Other major institutional holders of MRNA include Fidelity Management & Research (FMR), Capital World Investors, Baillie Gifford & Co, among 42 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.